Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Study Identifier:
D928EC00001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Will Be Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
- Drug: Placebo
Date
May 2025 - Feb 2028
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
- Drug: Placebo
Date
May 2025 - Feb 2028
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
Trial Locations
Location
Status
Location
Research Site
Phoenix, Arizona, United States, 85054
Status
N/A
Location
Research Site
Los Angeles, California, United States, 90095
Status
N/A
Location
Research Site
San Francisco, California, United States, 94115
Status
N/A
Location
Research Site
San Francisco, California, United States, 94143
Status
N/A
Location
Research Site
New Haven, Connecticut, United States, 06519
Status
N/A
Location
Research Site
Jacksonville, Florida, United States, 32224
Status
N/A